Hybio Pharmaceutical Co.,ltd
Hybio Pharmaceutical Co., Ltd. is a National High-Tech Enterprise specialized in R&D, manufacture and commercialization of peptide drugs.
Hybio owns over 12 peptides drug GMP certificates in China, having the largest market share in China. 5 API products have been approved by the EU and US authorities. 1 finish dosage ANDA has been submitted to the US FDA with several more being developed.
Hybio has a strong R&D capability, including the National Polypeptide Drug Development Laboratory and the Manufacturing Base of Polypeptide Drugs. Hybio went to public in Shenzhen Stock Exchange and became the first listed peptide producer in China (Stock Code: 300199).
Hybio is committed to the developing new medical products in chronic disease area such as diabetes, cardiovascular and nervous system diseases with peptide drugs as its core portfolio and high-end chemical and biological drugs as the supplements,.